Prospectus - Non-renounceable Entitlement Offer
Filed with ASX · · 53 pages · English
Summary by 6ix AI
Percheron Therapeutics Limited has issued a prospectus for a non-renounceable entitlement offer, allowing shareholders to purchase new shares and options at a specified price. Eligible shareholders must apply before the closing date, and the prospectus outlines the risks and details of the offer.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Percheron Therapeutics Limited on 6ix
Story so far
Earlier from Percheron Therapeutics
- Non-renounceable Entitlement Offer
- Half Yearly Report and Accounts
- Quarterly Activities/Appendix 4C Cash Flow Report
- Quarterly Activities Report and Appendix 4C
- Percheron Therapeutics Limited to Present at the Life Sciences Virtual Investor Forum September 18th
Later from Percheron Therapeutics
- Results of Entitlement Offer
- Percheron Therapeutics Announces CEO Succession
- Vanderbilt Health to conduct clinical trial of HMBD-002
- Percheron raises $2.3m to fully fund clinical trial in AML
Follow Percheron Therapeutics into a list and get an email when it puts out news.
Follow Percheron Therapeutics